Novo Nordisk halts FLOW trial early due to efficacy
Novo Nordisk announced the early stop of the FLOW trial, a Phase 3 study comparing kidney outcomes for injectable semaglutide 1.0 mg versus placebo in T2D and CKD.
The FLOW trial was designed to evaluate the renal safety and efficacy of semaglutide 1.0 mg compared with placebo in patients with type 2 diabetes and chronic kidney disease. This research context is relevant for understanding whether GLP-1 receptor agonists provide specific renoprotective benefits beyond glycemic control.
The trial was halted early following an interim analysis that met pre-specified criteria for stopping the study due to efficacy. Novo Nordisk announced this decision this week, indicating that the observed outcomes were sufficient to conclude the investigation without further data collection.
Results from the interim analysis demonstrated significant efficacy in meeting the primary endpoint of kidney outcomes. The authors noted that these findings met certain pre-specified criteria for early termination, suggesting a positive impact on renal parameters compared to placebo.
While specific statistical details remain pending, the trial's design focused on injectable semaglutide 1.0 mg versus placebo. Researchers have speculated that mechanisms such as inhibition of sodium-proton exchangers and suppression of renin-angiotensin-aldosterone system activity may contribute to observed renal benefits.
This study highlights ongoing interest in the potential for GLP-1 receptor agonists to slow chronic kidney disease progression. However, further details regarding long-term outcomes and broader applicability to non-diabetic CKD populations remain under investigation.